Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Cosimo BruniRoberta BittiFrancesca NacciLaura CometiLorenzo TofaniFrancesca BartoliGinevra FioriMarco Matucci-CerinicPublished in: Clinical rheumatology (2020)
Despite temporary changes in the concomitant medication profile for mild disease flares, our real-life data replicate the safety profile of switching from ADA to SB5 in RA, with additional data for its applicability in PsA and axSpA patients, further supporting switching to biosimilars in treating inflammatory rheumatic conditions. Key Points • Switching from adalimumab originator to SB5 is feasible in real life rheumatic inflammatory joint diseases. • Mild disease flares can present after switching from originator adalimumab to SB5, in particular in axial spondyloarthritis and psoriatic arthritis. • Changes in concomitant medications profile allows the control of minor disease flares presenting after switching from adalimumab originator to SB5.
Keyphrases
- rheumatoid arthritis
- disease activity
- juvenile idiopathic arthritis
- ankylosing spondylitis
- oxidative stress
- prostate cancer
- end stage renal disease
- electronic health record
- ejection fraction
- ulcerative colitis
- chronic kidney disease
- hidradenitis suppurativa
- healthcare
- emergency department
- machine learning
- systemic lupus erythematosus
- systemic sclerosis
- data analysis